[16] [17] Currently, there are no specific FDA-mandated bone density monitoring requirements for patients prescribed GLP-1 receptor agonists, as these medications have not been definitively linked to increased fracture risk or clinically significant bone loss in regulatory reviews
Following the recommended dose schedule gives your body time to adapt and may improve tolerance
However, modern research Read More Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s Jun 16, 2026 Articles, Diet and Nutrition, Exercise, Geriatric Medicine, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity 1,609 views The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment
FG: Formal analysis, Funding acquisition, Project administration, Resources, Validation, Visualization, Writing original draft
Strengthens bones, lowering osteoporosis risk